186Rhenium-labeled anti-CD20 antibody radioimmunotherapy followed by autologous peripheral blood stem cell transplantation in patients with relapsed or refractory non-Hodgkin lymphoma [1] (multiple letters)

Blood

Volumn 103, Issue 3, 2004, Pages 1175-

  Knop, Stefan ^a   Jakob, Andreas ^b   Kanz, Lothar ^b   Hebart, Holger ^b   Bares, Roland ^b   Dohmen, Bernhard ^b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; RITUXIMAB; RITUXIMAB RH 186; UNCLASSIFIED DRUG; MONOCLONAL ANTIBODY; RADIOISOTOPE; RHENIUM;

ADULT; ANTIBODY LABELING; AUTOTRANSPLANTATION; CANCER RECURRENCE; CASE REPORT; DOSE RESPONSE; DOSIMETRY; DRUG HALF LIFE; FEMALE; HUMAN; HUMAN TISSUE; ISOTOPE LABELING; LETTER; MALE; NEUTROPENIA; NONHODGKIN LYMPHOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; RADIOACTIVITY; RADIOIMMUNOTHERAPY; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT OUTCOME; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NOTE;

ADULT; ANTIBODIES, MONOCLONAL; COMBINED MODALITY THERAPY; FEMALE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RADIOIMMUNOTHERAPY; RADIOISOTOPES; RHENIUM; TRANSPLANTATION, AUTOLOGOUS;

EID: 1442351597     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-10-3593     Document Type: Letter

References (6)

1. Gopal AK, Gooley TA, Maloney DG, et al, High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis. Blood. 2003;102:2351-2357.
2. Kasina S, Rao TN, Srinivasan A, et al. Development and biologic evaluation of a kit for preformed chelate technetium-99m radiolabeling of an antibody Fab fragment using a diamide dimercaptide chelating agent. J Nucl Med. 1991;32:1445-1451.
3. Breitz HB, Weiden PL, Vanderheyden JL, et al. Clinical experience with rhenium-186-labeled monoclonal antibodies for radioimmunotherapy: results of phase I trials. J Nucl Med. 1992;33:1099-1109.
4. Press OW, Eary JF, Gooley T, et al. A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood. 2000;96:2934-2942.
5. Juweid ME. Radioimmunotherapy of B-cell non-Hodgkin's lymphoma: from clinical trials to clinical practice. J Nucl Med. 2002;43:1507-1529.
6. 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood. 2000;96:1259-1266.